262 related articles for article (PubMed ID: 20804735)
1. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
Yoshida S; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
[TBL] [Abstract][Full Text] [Related]
2. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
5. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice.
Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y
Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.
Zhang SY; Li J; Xie X
Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896
[TBL] [Abstract][Full Text] [Related]
7. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Biol Chem; 2014 Apr; 395(4):453-64. PubMed ID: 24323890
[TBL] [Abstract][Full Text] [Related]
8. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
9. GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.
Chepurny OG; Holz GG; Roe MW; Leech CA
Mol Endocrinol; 2016 Jun; 30(6):614-29. PubMed ID: 27082897
[TBL] [Abstract][Full Text] [Related]
10. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
11. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601
[TBL] [Abstract][Full Text] [Related]
12. 2-OMe-lysophosphatidylcholine analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells: Evaluation of structure-dependent biological activity.
Drzazga A; Sowińska A; Krzemińska A; Okruszek A; Paneth P; Koziołkiewicz M; Gendaszewska-Darmach E
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):91-103. PubMed ID: 29079451
[TBL] [Abstract][Full Text] [Related]
13. β-Cell Inactivation of
Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
[TBL] [Abstract][Full Text] [Related]
14. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
Kogure R; Toyama K; Hiyamuta S; Kojima I; Takeda S
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):58-63. PubMed ID: 22079287
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.
McKillop AM; Moran BM; Abdel-Wahab YH; Flatt PR
Br J Pharmacol; 2013 Nov; 170(5):978-90. PubMed ID: 23992544
[TBL] [Abstract][Full Text] [Related]
19. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
Chu ZL; Carroll C; Chen R; Alfonso J; Gutierrez V; He H; Lucman A; Xing C; Sebring K; Zhou J; Wagner B; Unett D; Jones RM; Behan DP; Leonard J
Mol Endocrinol; 2010 Jan; 24(1):161-70. PubMed ID: 19901198
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
